Title: Biden Administration Adds Insulin to List of Drugs for Negotiated Prices Under Medicare
In a significant step towards reducing healthcare costs, the Biden administration has included short-acting insulin in the list of drugs for which Medicare will negotiate lower prices. This move comes as part of the Inflation Reduction Act (IRA), which grants power to the White House to negotiate drug prices and tackle the rising cost of prescription medications.
The pharmaceutical industry, known for its robust lobbying efforts, heavily opposed the IRA, investing over $700 million to prevent its implementation. Nonetheless, the inclusion of insulin for negotiation in 2023 signals a significant victory for advocacy groups that have long campaigned for affordable drug prices.
Insulin, a crucial medication for individuals with diabetes, has become increasingly expensive in recent years. Leading manufacturers such as Eli Lilly, Novo Nordisk, and Sanofi have faced backlash for raising prices, leaving many patients struggling to afford their life-saving medication. The decision to negotiate lower prices for insulin aims to address these concerns and ensure access to affordable treatment options.
Advocacy groups, including Social Security Works and T1International, have actively fought for drug price negotiations and have rallied behind the inclusion of insulin. The IRA outlines clear criteria for drug inclusion, with the selection based on the highest spending drugs. Alongside insulin, nine other medications have been chosen for negotiation in 2023. These include Jardiance, Januvia, Farxiga, Eliquis, Xarelto, Stelara, Enbrel, Entresto, and Imbruvica.
Negotiations are set to begin later this year and conclude in 2024. The IRA aims to gradually expand the list of negotiable drugs in subsequent years to tackle the rising costs across the pharmaceutical industry.
The push for drug price negotiations has long been a key priority for Democrats, dating back to their campaign efforts in 2006. The savings generated from these negotiations will significantly improve the Part D drug benefit for seniors, allowing them to access medications at more affordable prices.
With the inclusion of short-acting insulin on the list of drugs for negotiation, the Biden administration is taking a crucial step towards making healthcare more accessible and affordable for all Americans. As the negotiations progress, many hope that this will be the first of many measures aimed at addressing the skyrocketing costs of prescription medications.
“Social media scholar. Reader. Zombieaholic. Hardcore music maven. Web fanatic. Coffee practitioner. Explorer.”